医学
家族性高胆固醇血症
低密度脂蛋白胆固醇
疾病
胆固醇
动脉粥样硬化性心血管疾病
临床试验
低密度脂蛋白受体
内科学
脂蛋白
作者
Étienne Khoury,Laurent Croteau,Alex Lauzière,Daniel Gaudet
出处
期刊:Future Cardiology
[Future Medicine]
日期:2022-06-01
卷期号:18 (6): 507-518
被引量:3
标识
DOI:10.2217/fca-2021-0149
摘要
Homozygous familial hypercholesterolemia (HoFH) is a life-threatening disease characterized by extremely elevated LDL cholesterol (LDL-C) levels which result in premature atherosclerotic cardiovascular disease. As conventional lipid-lowering therapies, which mainly depend on LDL receptors for LDL particle clearance, remain insufficient for reaching the recommended LDL-C levels in HoFH, agents acting independently of LDL receptors, such as ANGPTL3 inhibitors, constitute a promising target. Evinacumab, a monoclonal antibody directed against ANGPTL3, was approved in the USA in 2021 for treating patients with HoFH. Evinacumab has shown an adequate safety profile with strong LDL-lowering efficacy. This review highlights the development path of evinacumab and provides insight on the lessons learned from trials as well as the hurdles facing accessibility.
科研通智能强力驱动
Strongly Powered by AbleSci AI